Information Provided By: 
Fly News Breaks for June 26, 2017
REGN
Jun 26, 2017 | 07:52 EDT
As noted earlier, Bernstein downgraded Regeneron to Market Perform from Outperform. Analyst Aaron Gal downgraded the stock based on valuation and his belief that the shares reflect about $11B of peak sales for the company's Dupixent drug, which he believes is "far from certain." Target to $480 from $410.
News For REGN From the Last 2 Days
There are no results for your query REGN
